Advertisement
Advertisement
U.S. Markets close in 1 hr 40 mins
Advertisement
Advertisement
Advertisement
Advertisement

Acer Therapeutics Inc. (ACER)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0400+0.0300 (+1.49%)
As of 02:10PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.9900
Open2.0000
Bid2.0200 x 1800
Ask2.0700 x 900
Day's Range1.8600 - 2.0000
52 Week Range1.6800 - 5.3900
Volume57,021
Avg. Volume299,339
Market Cap29.193M
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update

    NEWTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2021 and provided an update on Acer’s recent corporate developments. “This quarter was all about preparing regulatory filings to advance our pipeline pr

  • GlobeNewswire

    Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation

    Key ACER-001 formulation composition of matter patent strengthens proprietary position in U.S. until 2036NEWTON, Mass. and GENEVA, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new U.S. patent to Acer for certain claims related to ACER-001 (sodium phenylbutyrate). Patent 11

  • GlobeNewswire

    Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation

    Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036NEWTON, Mass. and GENEVA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Acer’s patent application No. 17/196,416 for certain cl

Advertisement
Advertisement